Project Grant R43AR069400

This $644,864 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports preclinical studies by Ridgeline Therapeutics LLC, a Houston-based biotech company, to evaluate the efficacy of their lead compound RT-002 in preventing and reversing disuse-induced muscle atrophy in aging rat models. Specifically, the project aims to determine if RT-002 treatment can mitigate the loss of muscle mass and strength during muscle disuse, as well as improve the rate...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $216,113 to Weill Medical College of Cornell University to investigate inhibiting the GDF15-GFRAL signaling pathway as a potential therapy for treating cachexia and improving muscle function in a mouse model of mitochondrial myopathy. The project aims to determine if anti-GDF15 and...

This $306,872 Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA 93.846 is supporting Vivreon Biosciences, LLC, a life sciences company in San Diego, California, to develop a novel small molecule therapeutic targeting the ORAI1 calcium channel for treating Duchenne muscular dystrophy (DMD) and other dystrophinopathies. The key objectives of this 2-year project are to assess the toxicity profile of the therapeutic candidate and...

This $429,000 award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to investigate therapeutic strategies for rescuing metabolic deficiencies in spinal and bulbar muscular atrophy (SBMA). The project will leverage two SBMA mouse models to evaluate whether systemic administration of nicotinamide mononucleotide (NMN) can bypass deficiencies in the muscle...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $170,900.00 to Rowan University to research methods for optimizing autophagy to counteract aging-induced muscle deterioration (sarcopenia) in mice. The research aims to 1) define the role of the GAPR-1 protein in sarcopenia, and 2) determine the efficacy of combining the autophagy agonist TAT-Beclin1 with endurance exercise to...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA Program 93.859 Biomedical Research and Research Training provides $311,168 to Accelerated Muscle Biotechnologies Consultants, L.L.C. to develop infrastructure and capabilities for myocardial and skeletal muscle imaging using synchrotron radiation at the Brookhaven National Labs facility. The key objectives are to: 1) acquire muscle small-angle X-ray scattering (MYSAXS) data comparable to current...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,127,548 to the University of Texas Medical Branch at Galveston to investigate the role of post-translational modifications of myosin and its chaperone UNC-45 in the development of sarcopenia, the age-related loss of muscle mass and function. The project aims to use a combination of in vitro biochemical and biophysical assays, as well as in vivo techniques in the C. elegans model organism,...

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded Revidia Therapeutics, Inc. a $1,358,179 Project Grant to conduct IND-enabling safety and toxicity testing of a subcutaneous formulation of the PTP1B inhibitor MSI-1436. This novel therapy aims to treat fatal cardiomyopathy in patients with Duchenne muscular dystrophy (DMD), a leading cause of mortality in this population. The proposed studies will...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $1,292,847.00 to Advertent Biotherapeutics, Inc. to develop a novel therapeutic agent, ADA011, for preventing fatty degeneration of muscles in Limb Girdle Muscular Dystrophy 2B (LGMD2B). The funding will support long-term efficacy testing of ADA011 in a mouse model of LGMD2B and conduct...

This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $405,171 to the Oklahoma Medical Research Foundation (OMRF) to investigate the transcription factor TFEB as a potential therapeutic target for improving skeletal muscle function and recovery in aging. The key objectives are to determine if increasing TFEB activity can: 1) maintain muscle mass and function in aged mice, 2) regulate mTOR activity to preserve proteostasis, and 3) improve muscle...